Physician profile
Adaorah Abor
NPI 1225769631
$4,615.01
in general payments reported to CMS, 2019-2025
22 companies · $1,704 in 2025
The $1,704 reported for 2025 was more than what 90% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $300 · 2023: $1,276 · 2024: $1,335 · 2025: $1,704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,315.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $794.25 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $649.10 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $509.56 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $447.21 | 2022-2025 | Vraylar |
| Neurocrine Biosciences, INC. | $326.85 | 2022-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $284.00 | 2023-2025 | Auvelity |
| Lundbeck LLC | $272.31 | 2022-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $270.78 | 2022-2025 | Trintellix |
| Corium, LLC | $235.15 | 2022-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $171.49 | 2023-2025 | Spravato |
| Alkermes, INC. | $147.11 | 2023-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $116.69 | 2024-2025 | Fanapt |
| Idorsia Pharmaceuticals US INC | $102.19 | 2023-2024 | Quviviq |
| Supernus Pharmaceuticals, INC. | $68.93 | 2023-2025 | Qelbree, Qelbree |
| Noven Therapeutics, LLC | $42.08 | 2024 | Xelstrym |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $39.35 | 2023-2025 | Aplenzin, Wellbutrin |
| Tris Pharma INC | $35.92 | 2022-2025 | Onyda Xr |
| Collegium Pharmaceutical, INC. | $24.85 | 2025 | Jornay Pm |
| Noven Pharmaceuticals, INC. | $23.52 | 2024 | Xelstrym |
| Almatica Pharma LLC | $20.70 | 2024 | Loreev Xr |
| Neos Therapeutics, LP | $18.38 | 2023 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $14.59 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adaorah Abor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.